Technical Note: Low clinical efficacy, but good acceptability of a point-of-care electronic palpation device for breast cancer screening for a Lower Middle-Income environment
CONCLUSIONS: The iBE had generally poor sensitivity and specificity when tested in a clinical setting which does not allow its use as a screening tool.IMPACT: This study demonstrates the need for an alternative screening method other than electronic palpation for lower-middle income areas. This article is protected by copyright. All rights reserved.PMID:35106767 | DOI:10.1002/mp.15499 (Source: Health Physics)
Source: Health Physics - February 2, 2022 Category: Physics Authors: Dustin Valdez Teofila Cruz Stephanie Rania Grazyna Badowski Kevin Cassel Thomas Wolfgruber Scott Grosskreutz Louis J Dulana Roy Adonay Gertraud Maskarinec John A Shepherd Source Type: research
Technical Note: Low clinical efficacy, but good acceptability of a point-of-care electronic palpation device for breast cancer screening for a Lower Middle-Income environment
CONCLUSIONS: The iBE had generally poor sensitivity and specificity when tested in a clinical setting which does not allow its use as a screening tool.IMPACT: This study demonstrates the need for an alternative screening method other than electronic palpation for lower-middle income areas. This article is protected by copyright. All rights reserved.PMID:35106767 | DOI:10.1002/mp.15499 (Source: Health Physics)
Source: Health Physics - February 2, 2022 Category: Physics Authors: Dustin Valdez Teofila Cruz Stephanie Rania Grazyna Badowski Kevin Cassel Thomas Wolfgruber Scott Grosskreutz Louis J Dulana Roy Adonay Gertraud Maskarinec John A Shepherd Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
